Donations, sponsorship and payments
We care about our local community and about healthcare in the UK, and we proudly provide financial support to a variety of organisations through sponsorship and charitable donations. We also work in partnership with healthcare professionals for the benefit of patients, working together to enable better understanding and treatment of diseases in all our therapy areas. We believe that we have achieved far more working in partnership than we could ever have achieved alone.
Working in partnership means that we sometimes make payments to healthcare professionals, for example to reimburse them for their time and expertise in advising us about how our medicines can best meet patients’ needs, for speaking at meetings sharing best practice, and to support them in attending meetings and conferences that contribute to their continued development.
Napp is committed to complying with the requirements of the ABPI Code of Practice in the conduct of our business. As part of this commitment, we declare annually all payments made to UK healthcare professionals (HCPs). In addition we provide transparency on our interactions with, and support of patient organisations.
In compliance with the ABPI Code of Practice, all transfers of value to individual UK HCPs and HCOs (including those provided as grants, donations or benefits in kind) are to be disclosed in the first six months after the end of the calendar year in which the transfers of value were made. This can be found on the central ABPI disclosure platform; the disclosure platform can be accessed using the following web link: www.disclosureuk.org.uk.
For 2020, please see below information from the ABPI regarding disclosure of 2019 data during the exceptional COVID-19 pandemic period.
ABPI statement on disclosure of 2019 data during the COVID-19 pandemic in 2020
As part of the pharmaceutical industry’s annual disclosure of transfers of value to HCPs, ORDMs and HCOs via the Disclosure UK platform and in order to ensure accuracy of the published data, the ABPI writes to all of the HCPs, ORDMs and HCOs named in companies’ disclosure data ahead of its publication on Disclosure UK at the end of June. (Over 20,000 in June 2019.)
Given the unprecedented pressure on the NHS and health care professionals in responding to the COVID-19 pandemic, in April 2020 the ABPI and PMCPA agreed that it would not be appropriate for industry to write to HCPs, ORDMs or HCOs to request that disclosure data be reviewed. Doing so would add additional work for NHS professionals at this time. To avoid this, and in-line with guidance provided by the ABPI, Napp’s 2019 transfer of value data has been published on Disclosure UK in aggregate in June 2020. The 2019 data will be republished disaggregated as normal, on Disclosure UK at the end of November.
Commitment to transparency
The pharmaceutical industry is committed to preserving the integrity of Disclosure UK and transparency in our interactions with HCPs, ORDMs and HCOs. The ABPI continues to explore how the full disaggregated 2019 data can be submitted to Disclosure UK in line with data from previous years.
Support provided to patient organisations will continue to be disclosed as below and updated each year in the first six months after the end of the calendar year in which the transfers of value were made. You can see our previous declarations annually by clicking on the links below.